pharma · Non-small Cell Lung Cancer · Epilepsy
Eisai
Eisai Co.,
Eisai clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Tokyo, Japan, JP
- Employees
- 41
- Programs
- 22
- Drugs
- 31
- Patents
- 0
Eisai projects
7 ClinicalTrials.gov programs sponsored by Eisai.
Eisai has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
E0302 (mecobalamin)
Eisai Co.,
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
LECANEMAB
Eisai Co.,
Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid
1 trial -
Lecanemab
Eisai Co.,
Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.
1 trial -
Pembrolizumab
Eisai Co.,
Endometrial Neoplasms
1 trial -
Zonisamide
Eisai Co.,
Epilepsy
1 trial -
bexarotene
Eisai Co.,
Non-small Cell Lung Cancer
1 trial -
perampanel
Eisai Co.,
Epilepsy
2 trials
Frequently asked questions
How many clinical projects does Eisai have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.